The drug, developed by Paris-based Sanofi and Tarrytown, N.Y.-based Regeneron Therapeutics, could earn approval by next March, reports Reuters.
The priority review process, which expedites the review of a drug application to about six months after filing, was created to decrease the time it takes to put new medicines on the market.
More articles on supply chain:
Mylan working on EpiPen formulation with longer shelf life
FDA fast tracks malaria vaccine
Intermountain Healthcare recognizes 4 suppliers for outstanding work
